DaVita Inc
DUS:TRL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
DaVita Inc (TRL) under the Base Case is 216.19 EUR per share.
Compared with the current market price of 162.3 EUR, the stock appears
Undervalued by 25% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What DaVita Does
DaVita is a healthcare company focused on kidney care. Its main business is running dialysis centers, where it treats patients whose kidneys can no longer clean waste from the blood properly. It also offers related care services for people with chronic kidney disease, including support before dialysis starts and help managing long-term treatment.
- Headquarters
- United States of America US
- Employees
- 78 000
- IPO date
- Oct 31, 1995
DaVita has a narrow economic moat
Buying supplies in bulk and spreading support costs across its clinics help DaVita deliver dialysis more cheaply than smaller providers. In some communities, existing clinics already serve much of the available patient population, leaving little room for a newcomer to operate profitably. These protections are stronger against small entrants than against its large rival, Fresenius Medical Care.
Read the full moat analysis
Revenue & Expenses Breakdown
DaVita Inc
Earnings Waterfall
DaVita Inc
What is the Intrinsic Value of one TRL stock?
The intrinsic value for DaVita Inc (TRL) under the Base Case is 216.19 EUR.
Is TRL stock undervalued or overvalued?
Compared with the current market price of 162.3 EUR, the stock appears Undervalued by 25% .
